ABBV-075 exhibited anti-leukemic efficacy in patients with relapsed/refractory AML, and its effectiveness was further potentiated when combined with the BCL2 selective inhibitor, venetoclax [41]. Here, BCL2 is linked to acute myeloid leukemia.